Floatz logo

rc48-adc

Locally Advanced Prostate Cancer

Shanghai Changzheng Hospitalantibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Locally Advanced Prostate Cancer cohort.

Asset / SponsorPhaseRating
Pyrotinib
Shanghai Changzheng Hospital
Phase 2B
Goserelin Microspheres For
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Pamiparib
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Tnferade™
Phase 1CC

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →